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Running title: Commonalities in iGluRs global gene profiles 
 
 
Abstract: 
 
 
Excitotoxicity, induced by the aberrant rise in cytosolic Ca2+ level, is a major neuropathological 
process in numerous neurodegenerative disorders. It is triggered when extracellular glutamate (Glu) 
concentration reaches neuropathological levels resulting in dysregulation and hyper-activation of 
ionotropic glutamate receptor subtype (iGluRs). Even though all three members of the iGluRs, 
namely N-methyl-D-aspartate (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPAR) and kainate (KAR) receptors are implicated in excitotoxicity, their individual 
contributions to downstream signaling transduction have not been explored. In this study, we report a 
comprehensive description of the recruitment of cellular processes in neurons upon iGluR activation 
during excitotoxicity through temporal (5h, 15h and 24h) global gene profiling of AMPA, KA, 
NMDA and Glu excitotoxic models. DNA microarray analyses of mouse primary cortical neurons 
treated with these four pharmacological agonists are further validated via real-time PCR. Bi-model 
analyses against Glu model demonstrate that NMDARs and KARs play a more pivotal role in Glu-
mediated excitotoxicity, with a higher degree of global gene profiling overlaps, as compared to that 
of AMPARs. Comparison of global transcriptomic profiles reveals aberrant calcium ion binding and 
homeostasis, organellar (lysosomal and endoplasmic reticulum) stress, oxidative stress, cell cycle re-
entry and activation of cell death processes as the main pathways that are significantly modulated 
across all excitotoxicity models. Singular profile analyses demonstrate substantial transcriptional 
regulation of numerous cell cycle proteins. For the first time, we show that iGluR activation forms 
the basis of cell cycle re-activation, and together with oxidative stress fulfill the “two-hit” hypothesis 
that accelerates neurodegeneration. 
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1. Introduction 
 
Excitotoxicity is a general term that defines a damage-inflicting cellular process mediated via 
overstimulation of receptors for L-glutamate (GluRs) to effect a rise in cytosolic calcium ion level 
and occurs principally as a result of a constitutive and hyper-activation of ion channel-gated GluRs 
(iGluRs) and other types of calcium channels (Arundine and Tymianski, 2003).  Because cellular 
indices reflecting excitotoxic damage are altered early in the pathogenesis of various 
neurodegenerative diseases such as Alzheimer’s disease (AD; (Hynd et al., 2004)), dementia 
associated with Down syndrome (DS; (Scheuer et al., 1996)) and acute neurological deficits due to 
traumatic brain injury (TBI) and stroke (Arundine and Tymianski, 2004), excitotoxicity is believed to 
be one of the primary upstream events that induces neuronal injury at a cellular level. An 
extracellular rise in the concentration of L-glutamate (Glu) in the micro-environment of the brain is 
recognized as a key trigger for initiating excitotoxicity and has been documented in conditions such 
as hypoglycemia or status epilepticus (Costa et al., 2004; Ding et al., 2007; Wieloch et al., 1985). 
Hypoglycemia is commonly observed during both stroke and an episode of TBI where ischemic 
reduction in blood flow limits supply of oxygen and glucose to a localized region of the brain. These 
events then lead to inadequate ATP production which abolishes the electrochemical gradients 
required to maintain functionality of inward-rectifying Glu transporters in astrocytes, resulting in an 
accumulation of extracellular Glu. To further complicate matters, the loss of electrochemical 
gradients reverses the channeling action of these transporters, causing them to release Glu into the 
extracellular space. This reversal has important neuronal implications as it further enhances the 
accumulation of extracellular Glu, which then causes a potentiation of dysregulated GluRs in 
neighboring neurons, leading to intracellular calcium imbalance and subsequently and their demise 
(Beart and O’Shea , 2007). 
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Basically, Glu is the only physiological excitatory neurotransmitter agonist for GluR activation in the 
mammalian brain. Because GluRs activation is a major determinant of synaptic plasticity, it plays an 
important role in structuring neurocognitive processes underlying memory and learning (Mukherjee 
and Manahan-Vaughan, 2012). The subunit composition and sequence homology of each GluR in its 
superfamily have been extensively studied and depending on their individual mode of activation, they 
are grouped into either metabotropic (mGluRs) or ionotropic (iGluRs) GluRs (Niciu et al., 2012). 
While mGluRs indirectly activate ion channel via signaling pathways that involve G proteins, iGluRs 
possess intrinsic ion channel activities. Therefore, during excitotoxicity, neuronal cell death is 
mediated by two concurrent yet distinct signaling processes determined by both iGluRs and mGluRs 
(Lea and Faden, 2003).   
 
In particular, iGluRs are made up of N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) and kainate (KA) receptor subtypes which are named after their 
specific pharmacological agonists active at different intrinsic ligand-gated ion channel activity that 
allows passage of Na+ and Ca2+ ions through a pore. All three subtypes of iGluRs (NMDAR, 
AMPAR and KAR) are actively involved during excitotoxic neuronal cell death. The NMDAR plays 
a major role due to its abundant expression and highest Ca2+ permeability (Hara and Snyder, 2007). 
Studies have shown that excessive NMDAR activation induces Ca2+ influx and release from 
intracellular stores, resulting in the activation of cytoplasmic proteases such as calcium-activated 
calpains (Simpkins et al., 2003) that hydrolyze cytoskeletal proteins. An example of such cytoskeletal 
protein is α-fodrin (Posner et al., 1995; Siman et al., 1989). Furthermore, NMDAR activation can 
result in the destabilization of lysosomes and the release of lysosomal cathepsins, causing cell death 
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(Graber et al., 2004; Tenneti et al., 1998). Likewise, dysregulation of AMPAR and KAR also induces 
excitotoxicity in neurons (Jayakar and Dikshit, 2004; Sattler and Tymianski, 2001; Vincent and 
Mulle, 2009). Indeed, we were the first to demonstrate that AMPA alone could produce apoptotic-
like injury (Larm et al., 1997), just as can KA, with injury likely to exert an apoptotic-necrotic 
continuum of programmed cell death (Cheung et al., 1998). 
 
To date, the consequences of activation of individual iGluRs subtypes in downstream signal 
transduction during excitotoxicity has not been comprehensively and simultaneously explored in a 
comparative platform, impeding an understanding of the relative contributions of individual iGluRs, 
be that via convergent or divergent cellular pathways, towards excitotoxic damage. In our current 
study, global transcriptomic profiling was employed to elucidate downstream signaling pathways, in 
terms of amplification and diversification, subsequent to different iGluR activation to model the 
sequence of events subsequent to extracellular Glu in the brain reaching pathological concentrations. 
Here, the DNA microarray technique was applied to four excitotoxic models induced by a) the 
general GluR agonist, Glu, b) AMPAR agonist, AMPA, c) NMDAR agonist, NMDA and d) KAR 
agonist, KA. Subsequent comparative global gene profile analysis was performed to elucidate the 
major primary biological processes regulated by iGluRs in the trigger of excitotoxicity during Glu-
mediated neuronal injury. Our study is the first to attempt global gene profiling of this type and scale 
to elucidate the pathobiology of excitotoxicity. Briefly, oxidative stress and cell cycle re-activation 
were identified as the primary cellular pathways that were significantly modulated. The specific 
association of cell cycle-reactivation with iGluR activation provided interesting evidence for the 
occurrence of a ‘two-hit’ hypothesis in excitotoxicity that has been previously postulated by others 
for the basis of neurodegeneration in AD pathogenesis (Zhu et al., 2004, 2007). 
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2. Materials and methods 
 
2.1 Murine Neocortical Neuronal Cultures 
 
Neocortical neurons (gestational days 15 or 16) obtained from foetal cortices of Swiss albino mice 
were used to prepare the primary cultures as previous described with minor modifications (Cheung et 
al., 2000). Dissected cortices were subjected to trypsin digestion and mechanical trituration. Cells 
were collected by centrifugation and resuspended in Neurobasal (NB) medium containing 2.5% 
B27 supplement, 1% penicillin, 1% streptomycin, 0.25% GlutaMAX-1 supplement and 10% dialyzed 
foetal calf serum. 24-Well plates previously coated with poly-D-lysine (100g/ml) were seeded with 
cells to a density of 2 105 cells/cm2 and used for subsequent experiments. Cultures were maintained 
in a humidified 5% CO2 and 95% air incubator at 37°C. Immunocytochemical staining of the cultures 
at day 5 in vitro for microtubule-associated protein-2 and glial fibrillary acidic protein revealed > 
95% of the cells were neurons with minimal contamination by glia (Cheung et al., 1998). All 
experiments involving animals were approved by the National University of Singapore, and were in 
accordance with the US Public Health Service guide for the care and use of laboratory animals. 
 
2.2 Drug Preparation and Treatment 
 
Glu, NMDA, KA and S-AMPA (Sigma-Aldrich) were freshly prepared prior to usage to achieve 
stock concentrations of 100mM. Working concentrations (Glu 250 µM, NMDA 200 µM, KA 100 
µM and S-AMPA 300 µM) were achieved by dilution with NB medium. 
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2.3 Total RNA extraction and isolation 
 
RNA was extracted using RNeasy Mini Kit (Qiagen Cat. No. 74104) according to the manufacturer’s 
instructions. All pipette tips used were RNase-free. Each sample was prepared from 1  106 cultured 
cells. RNA concentration was determined spectrophotometrically using Nanodrop ND-1000 Version 
3.2.1 and RNA quality was determined using a E-gene HDA-GT12 genetic analyzer. 
 
2.4 Microarray analysis using Illumina Mouse Ref8 Ver.1.1 hybridization beadchips  
 
Microarray was carried out using Illumina Mouse Ref8 Ver.1.1 arrays. For each GluR agonist 
treatment, the assignment of the arrays was as follow: 5h (n=3), 15h (n=3), and 24h (n=3) and control 
(n=6). Each RNA sample (500ng) was reverse transcribed using T7 Oligo(dT) primer to form first 
strand cDNA containing a T7 promoter sequence, which was subsequently used for the second strand 
cDNA synthesis (employing DNA polymerase and Rnase H to simultaneously degrade the RNA and 
to synthesize second strand cDNA). The cDNAs were purified to remove RNA, primers, enzymes, 
and salts that would inhibit in vitro transcription. Finally in vitro transcription was employed to 
generate multiple copies of biotinylated cRNA from the double-stranded cDNA templates. All 
previously mentioned procedures were performed using Illumina® TotalPrep RNA Amplification 
Kit. cRNA yields were quantitated using the NanoDrop ND-1000. 
 
cRNA (750ng) prepared in RNase-free water (5l) was mixed with hybridization buffer (10l) and 
preheated to 65°C for 5min. Assay samples were then fully loaded onto the large sample port of each 
array on the beadchip. Beadchips were incubated in a humidified hybridization chamber at 58°C for 
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17h. The following day, the IntelliHyb seal on the beadchip was removed to expose all the arrays. 
Beadchips were blocked and labeled with streptavidin-Cy3, followed by stringency buffer washes 
and dried. The hybridization process was carried out according to the manufacturer’s instruction 
(Illumina Inc.). Beadchips were then ready for scanning on the Illumina scanner using Bead Studio 
software at Scan Factor = 0.8. 
 
2.5 Microarray data collection and analysis 
 
Initial analysis of the scanned images was performed using BeadScan (Illumina). The absolute data 
(signal intensity, detection call and detection P-value) were exported into GeneSpringGX 7.3 
(Agilent Technologies, CA, USA) software for analysis by a parametric test based on crossgene error 
model (PCGEM). A one-way analysis of variance (ANOVA) approach was used to identify 
differentially expressed genes. Array data were globally normalized using GeneSpring software. 
Firstly, all measurements on each chip were divided by the 50th percentile value (per chip 
normalization). Secondly, each gene was normalized to the baseline value of the control samples (per 
gene normalization) using median. Then genes were filtered on fold change 1.5 fold against controls 
in at least one of three conditions for each respective treatment. Finally, one-way ANOVA (p <0.05) 
and Benjamini-Hochberg False Discovery Rate (FDR) Correction were used to seek differentially 
expressed genes. Genes which were differentially expressed are annotated according to Gene 
Ontology-Biological process provided by the online bioinformatics resources Database for 
Annotation, Visualization and Integrated Discovery (DAVID) 6.7 (http://david.abcc.ncifcrf.gov/) 
(Dennis et al., 2003; Huang et al., 2009). All microarray data reported here are described in 
accordance with MIAME guidelines, and has been deposited in the NCBIs Gene Expression 
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Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession 
number GSE16035, GSE22993, GSE22994 and GSE19936. 
 
2.6 Real-time polymerase chain reaction (PCR) 
 
Eight differentially expressed genes were selected for validation of the microarray results in replicate 
by quantitative real-time PCR in three independent experiments. The same total RNAs used for 
microarray from mouse culture treated with 250 μM Glu were reverse transcribed to cDNAs 
according to steps specified by the manufacturer (Applied Biosystems Taqman reverse transcription 
reagents). The experiment set up, briefly, consisted of Taqman master mix (20l) and cDNA or water 
(NTC; both 5l) was added to the designated reaction well of a real-time PCR plate. The plate was 
then read using the 7000 Fast Real-Time PCR System with conditions according to the 
manufacturer’s protocol. 
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3. Results 
 
Overall, cellular transcriptional regulation was assessed in excitotoxic models employing 250 µM 
Glu, 200 µM NMDA, 300 µM AMPA and 100 µM KA over a 24-hour period using Illumina 
Mouse Ref8 V1.1 genechips. The raw transcriptional signal data from individual arrays were then 
subjected to statistical filtering using one-way ANOVA, p <0.05 and Benjamini-Hochberg FDR. 
Gene probes were considered to be significantly regulated when they demonstrated gene expression 
changes of at least  1.5 folds in a minimum of one out of the three time-points (5h, 15h and 24h). 
All gene probes that passed these selection criteria were gathered to form the global transcriptomic 
data for each excitotoxic model. Transcriptomic profiles generated from the treatment of neurons 
with Glu (1,842 gene probes), NMDA (2,309 gene probes), AMPA (1,563 gene probes) and KA 
(3,800 gene probes) were organized side-by-side and partitioned to different fold-change categories 
(Figure 1). A substantial number of gene probes demonstrated greater than 1.5 fold-changes in gene 
expression over the 24-hour period, with KA treatment generating the largest transcriptomic profile.   
 
3.1 Bi-model analyses of individual iGluRs profiles against that of Glu revealed the 
following decrease ordering of iGluRs activation dependence 
NMDARs>KARs>AMPARs during excitotoxicity 
 
Bi-model global transcriptomic profile comparisons using Glu model as the basis of analysis 
demonstrated that in rank order of highest to lowest degree of overlap, i.e. commonly occurring and 
differentially regulated gene probes, NMDA > KA > AMPA (Figure 2). NMDA (Figure 2A) and KA 
(Figure 2C) profiles were comparable, but they exhibited nearly double the number of Glu commonly 
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occurring genes when compared to AMPA profile (Figure 2B). These profiles signify a greater 
reliance upon NMDAR and KAR-mediated signaling pathways to induce excitotoxicity during Glu-
mediated neurotoxicity. A more in-depth analysis of the consistency in transcriptional regulatory 
trend demonstrated that the majority of the genes were similarly regulated at 15h and 24h 
respectively in all three iGluRs models (Figure 3). 
 
3.2 Simultaneous comparison of all four excitotoxic models identified several major 
common biological processes 
 
A concerted transcriptomic analysis of all four profiles revealed a total list of 583 common genes. 
Similarly, a detailed exploration of the transcriptional trend of these genes revealed a high degree of 
consistency at each respective time-point, which faltered upon inter-time-point examination across all 
three time-points (Figure 4), indicating a common temporal activation and/or inhibition of signaling 
pathways across all four excitotoxicity models, but with distinct progression outcome of each 
signaling cascade, i.e. either pursuant and persistent maintenance of initial activated/inhibitory state 
or directional change of pathway regulation.  
 
Functional classification of these 583 RefSeq transcripts, which corresponded to 485 biologically-
annotated genes, identified several important and over-represented biological pathways relevant to 
the progression of excitotoxicity (Table 1). These include calcium homeostasis and binding, anti-
oxidant response, cell death and cell survival processes. Notably, an overwhelming number of 
molecules involved in the promotion of mitotic cell cycle progression were transcriptionally elevated 
in all four models of excitotoxicity. Consistently, all members of these over-represented biological 
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processes were significantly modulated at the expression level between the 5h and 15h time-points, 
implying the reported pathways constitute the early upstream cellular events in excitotoxicity. 
 
I. Calcium ion homeostasis and binding: In all four excitotoxic models, genes encoding for 
Ca2+-dependent proteins and receptors (Gpr12, Prkcb and Rxfp3) were significantly down-
regulated, indicating the occurrence of aberrant calcium ion homeostasis. On the contrary, 
genes encoding for Ca2+-binding proteins (S100a6 and Anx (A2, A3 and A5) showed 
increased gene expression, providing further evidence of elevation of cytosolic Ca2+level 
during excitotoxicity due to activation of iGluRs which triggers intrinsic Ca2+channel activity. 
 
II. Lysosomal stress: Aberrant elevation of cytosolic Ca2+ ion level and overproduction of 
reactive oxygen species (ROS) imposes organellar stress through disruption of the delicate 
balance of cellular ionic gradients and unregulated modifications of cellular proteins resulting 
in detrimental loss/gain-of function, all contributing to disturbance of normal cellular 
signaling. Analysis of the gene profiles of genes common to all four excitotoxic models 
revealed significant transcriptional activation of lysosomal resident proteins, indicative of 
some form of disorientation and/or stress imposed on the normal functioning of the 
lysosomes. 
 
III. Anti-oxidant responses 
Heat shock proteins (Hsps) and molecular chaperones: Organellar (ER and lysosomal) 
stress is especially prominent in excitotoxicity and evokes a cellular counteractive response to 
minimize electrophilic and oxidative burdens. Interestingly, comparative microarray analysis 
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demonstrated that in our specific iGluR excitotoxic models, up-regulation of the majority of 
genes encoding for heat shock proteins (HSPs) and molecular chaperones (Hmox1, Srxn1, 
Hspa2, and Hspb8) and metal chaperones (Mt3) occurred at the 5h time-point, much earlier 
than that of Glu at 15h. 
 
Glutathione (GSH) metabolism: Genes transcribing for members of the GSH anti-oxidative 
pathway were significantly up-regulated in all four models. However, AMPA and Glu models 
demonstrated significant elevation of GSH pathway genes at 15h, while NMDARs and KARs 
demonstrated earlier transcriptional response at 5h. 
 
IV. Cell death: Majority of the genes encoding for proteins directly/indirectly involved in 
promotion of cell death (Angptl4, Casp6 and Ctnna1) were transcriptionally up-regulated. In 
addition, cell death was further accelerated by the down-regulation of anti-cell death protein 
(Bcl11b). 
 
V. Cell homeostasis, survival and proliferation: In all four excitotoxic models, genes encoding 
for pro-survival/mitogenic proteins (Spp1 and Birc5 (also known as Survivin)) and growth 
factors (Igf2 and Igfbp5) were up-regulated between the 5h and 15h time-points. These 
responses indicate a cellular response to suppress cell death mechanisms. 
 
VI. Mitotic cell cycle: Numerous genes encoding for cell cycle proteins that promote cell cycle 
re-entry were up-regulated in all four excitotoxic models between 5h and 15h. This 
observation is totally unprecedented in the context of excitotoxicity. Under physiological 
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conditions, neurons are in the post-mitotic and differentiated state. Aberrant cell cycle re-
entry has been implicated in the pathogenesis of several neurological conditions such as AD, 
DS, Huntington’s disease, Pick’s disease and stroke (Camins et al., 2008; Pelegri et al., 2008). 
Recent studies on AD suggested this cellular event to be a part of the neuronal death process 
(Lopes et al., 2009a, 2009b). p53, the main keeper of genome integrity, was significantly 
down-regulated (denoted as Trp53 in the table), indicating a failure in the cell cycle 
checkpoint system that enhances re-activation of cell cycle process. 
 
3.3 Singular profile analysis highlights cell cycle re-activation as a prominent biological 
process during excitotoxicity 
 
The majority of proteins involved in mitotic cell cycle process showed significant transcriptional 
modulation across all four profiles (Table 2). Gene expression of proteins promoting positive regulation 
of mitosis occurred between 5h and 15h post-treatment, providing strong evidence for the early 
occurrence of cell cycle re-entry upon iGluRs induction. Detailed temporal fold-expression of individual 
genes can be found in Supplementary Tables 1-4. 
 
3.4 Validation of Glu global transcriptomic profiles via real-time PCR 
 
Microarray data were validated via real-time PCR using the same total RNA samples previously 
employed for microarray analysis. Similar temporal transcriptional regulatory trends were observed 
for the genes listed in Table 3.  
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4. Discussion 
 
Excitotoxicity is well accepted to be a cell death process contributing to both acute and chronic 
neurodegenerative conditions (Doble, 1999). Although rises in intracellular Ca2+ subsequent to 
activation of NMDARs play a central role in most discussions of excitotoxicity, the recruitment of 
cell signaling cascades is likely to be more complex. Here, we sought to determine the individual 
contributions of over-stimulated iGluRs to the excitotoxic process by transcriptomic profiling. The 
rationale here was that gene expression profiling using the robust approach of primary cultured 
neurons with well controlled experimental conditions would allow a thorough understanding of 
which molecules are involved downstream of individual iGluR activation and then contribute 
towards the excitotoxic process of neuronal cell death. Previously, we have demonstrated the 
expression of functional iGluRs in our neuronal culture model (Cheung et al., 2007). Key findings 
obtained by comparison of global transcriptomic profiles were that the main pathways modulated 
across all excitotoxic models were calcium ion binding and homeostasis, organellar stress, oxidative 
stress, cell cycle re-activation and activation of cell death processes. Notably, we show for the first 
time that iGluR activation forms the basis of cell cycle re-activation, and that with oxidative stress 
they together fulfill the “two-hit” hypothesis that accelerates neurodegeneration.  
 
Simultaneous comparison of the global transcriptomic profiles of AMPA-, KA-, NMDA- and Glu-
mediated excitotoxic injury revealed a higher degree of correlation in terms of number of similarly-
regulated genes for KA and NMDA, rather than AMPA profiles, versus that of Glu as background. 
Importantly, these data suggest that as compared to AMPARs, a higher amplification of signalling 
transduction from KARs and NMDARs activation may be due to their greater expression on cell 
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surfaces, which often have a direct graded influence on intrinsic receptor ionic conductance and/or 
recruiment of elicited downstream pathways. Other than not being as highly expressed as NMDARs, 
AMPARs are depolarized before NMDARs and they demonstrate differential Ca2+ permeability 
which is governed by the presence or absence of the GluR2 subunit (Bassani et al., 2009; Wright and 
Vissel, 2012). As such, the presence or absence of GluR2 plays a crucial role in AMPAR-mediated 
Ca2+ influx in neurons under Glu stimulus. Based on these reported physiological differences, a 
different transcriptomic profile might be expected. In the case of Glu, delay in cellular process 
activation may be accounted by dilution of the effective concentration of the agonist to activate 
iGluRs, due to concurrent sequestration of Glu molecules by mGluRs and Glu transporters. 
 
Functional annotation revealed oxidative stress and cell cycle re-activation as the main cellular 
components triggered by excitotoxicity. Presence of oxidative stress is likely a response to the 
transcriptional upregulation of organellar (ER/lysosomal) stress-inducible genes and anti-oxidant 
proteins such as Hsps, molecular chaperones and GSH enzymes. More interesting was that the origin 
of cell cycle-reactivation has been defined for the first time and clearly linked to iGluR activation. 
Overall, simultaneous transcriptional upheaval of both processes supports the “two-hit” hypothesis 
originally formulated for AD pathogenesis (Zhu et al., 2001, 2004, 2007), suggesting that oxidative 
stress and cell cycle dysregulation contribute hand-in-hand to neuronal loss during 
neurodegeneration. 
 
Temporal global transcriptomic profiles of models of excitotoxicity demonstrated significant 
modulation of mitotic cell cycle process, with an up-regulation observed for the majority of the cell 
cycle-promoting proteins. For years, the precise origins of mitotic dysfunction have not been fully 
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understood. Cell cycle re-activation association to excitotoxicity has previously been reported on 
numerous occasions in models of excitotoxicity and stroke, amidst models of other 
neurodegenerative diseases such as the MPTP model of Parkinson’s disease (PD) and superoxide 
dismutase-1 mouse model of amyotropic lateral sclerosis (ALS) (Hoglinger et al., 2007; Nguyen et 
al., 2003; Verdaguer et al., 2003,2004a), indicating a similar neuropathological incidence between 
these two cellular events which may not be a coincidence. Importantly, our study employing a 
comparative temporal microarray technique demonstrated that iGluR activation plays an important 
role in the trigger of cell cycle re-activation during Glu-mediated excitotoxicity, and that downstream 
signaling via iGluRs may be the origin or an important part of the cause of mitotic dysfunction.  
 
Aberrant expression of neuronal cell cycle proteins with resultant neuronal loss has been observed in 
post-mortem tissue from patients with neurodegenerative diseases such as AD, PD, ALS, DS and 
progressive supranuclear palsy (Nunomura et al., 2007; Woods et al., 2007) and acute neurological 
disorder such as stroke and TBI (Byrnes and Faden, 2007; Timsit and Menn, 2007). Accumulating 
evidence has demonstrated aberrant expression of cell-cycle-related molecules in the neurons of the 
hippocampus, subiculum, locus coeruleus and dorsal raphe nuclei. Our novel evidence is further 
substantiated by proof of DNA replication in brains of patients with AD (Busser et al., 1998; McShea 
et al., 1997; Vincent et al., 1997; Yang et al., 2001), epilepsy (Nagy and Esiri, 1998), PD (Jordan-
Sciutto et al., 2003)  and ALS (Ranganathan and Bowser, 2003).  
 
Neurons in the adult central nervous system exist in the quiescent state i.e. a non-dividing, silent 
phase, called G0. Cells in this state are designated as terminally differentiated as they do not have the 
ability to re-enter cell cycle (McShea et al., 1999). Increasing evidence from neurodegenerative 
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diseases studies demonstrates that these mitotically inactive neurons often become the vulnerable 
targets of aberrant cell cycle re-entry (Lee et al., 2009; McShea et al., 2007; Zhu et al., 1999, 2007). 
It is likely that under the influence of over-activated iGluRs during excitoxicity, re-entrant neurons 
that proceed beyond the late G1, or even enter and complete S-phase, cannot return to G0. As a result 
of some undefined cellular constraints of terminally differentiated neurons, the cell cycle re-entrant 
cells being neither able to return to quiescent state or complete mitosis, induce their own deaths via 
programmed cell death pathways (Meikrantz and Schlegel, 1995; Wang et al., 2009). Such a fate was 
evident from the elevated level of pro-apoptotic genes and concomitant down regulation of anti-
apoptotic genes as highlighted previously. During cell transitions from S-phase to M-phase in 
mitosis, cyclins and their associated cyclin-dependent kinases (CDKs), fluctuate in their expression 
and activity (Grana and Reddy, 1995). In particular, the expression and activation of cyclin 
D/CDK4,6 complex, triggered by the presence of mitotic growth factors, facilitates the passing from 
resting (G0) cells into the G1 phase of cell cycle (Sherr, 1994, 1995). Similarly, the G1/S transition is 
governed by the activation of the cyclin E/CDK2 complex (Sherr, 1994), such that the absence of 
cyclin E and/or the inhibition of the cyclin E/CDK2 complex by p21, p27 and p53 would impose cell 
cycle arrest at the G1 checkpoint. 
 
From profiling the genes involved in mitotic cell division for individual excitotoxicity (Table 2), it is 
apparent that numerous cell cycle-promoting proteins were transcriptionally up-regulated from 5h 
and 15h. This finding is in agreement with an increase in gene expression of pro-mitogenic signals 
from growth factors. Interestingly, transcriptional up-regulation of cyclin D1 and D2 was observed in 
AMPA and KA models, but not in the NMDA and Glu models. This difference in temporal 
modulation of cyclin D could be explained by the earlier occurrence of cell cycle re-activation before 
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the selected 5h time-points in NMDA and Glu profile as a result of the highest physiological 
abundance and calcium ion permeability of NMDARs out of the three iGluRs subtypes, which leads 
to the failure to capture the timeframe of cyclin D transcriptional modulation. As such, NMDA 
profiling demonstrated basal fold-change (~1.0) at 5h, followed by significant pursuing down-
regulation at 15h and 24h. On the other hand, L-cyclin D (Ccnd) transcriptional regulation was not 
present in the Glu profile, indicating an overall close to basal (between -1.50 to 1.50 fold) expression 
due to a neutralizing effect from the up and down-regulation of Ccnd in AMPA/KA and NMDA 
profiles respectively upon all iGluRs activation. 
 
While activation of iGluRs during excitotoxicity may be the trigger for the initiation of cell cycle 
reactivation, oxidative stress may further facilitate and promote its progression (Bonda et al., 2010). 
Indeed, significant oxidative load, represented by the substantial transcriptional activation of Hsps, 
molecular chaperones and GSH pathway associated genes, was observed across all four 
excitotoxicity models. Oxidative stress in particular has been strongly linked to excitotoxic neuronal 
cell death in both multiple sclerosis and brain ischemia (Gonsette, 2008; Warner et al., 2004). 
Intriguingly, our study highlights that a “two-hit” hypothesis, originally put forward for 
neurodegeneration in AD, involves both oxidative stress and aberrant cell cycle activation may apply 
to neuronal excitotoxicity (Zhu et al., 2001, 2007). In the current study, apart from oxidative stress, 
the two conditions paramount for aberrant cell cycle re-entry occur in neurons, namely (a) an 
elevation in cell cycle proteins and (b) an increase in pro-mitogenic signals, have been fulfilled. Even 
though mature neurons may express some cell cycle proteins, the amount produced is not sufficient 
to produce a substantial pro-mitogenic signal to drive the mature neuron to re-enter the cell cycle. 
Furthermore, some cell cycle proteins demonstrate diverse post-mitotic multi-functions that span 
various developmental stages of a neuron, including neuronal migration, axonal elongation, axonal 
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pruning, dendrite morphogenesis and synaptic maturation, and plasticity (Frank and Tsai, 2009; Kim 
et al., 2009). As such, neuronal cell death requires the additional stimulus of pro-mitogenic 
molecules, such as thrombin, Aβ, ROS, nitric oxide and elevations in the level of such molecules will 
then trigger the mitogenic signaling cascades in injured neurons. Once mitogenic signaling is 
stimulated beyond a certain threshold, neurons appear to exit their quiescent state and re-enter the 
cell cycle and this “vulnerable” state eventually leads to their demise (Bonda et al., 2010). 
 
To date, preclinical experiments employing inhibitors (flavopiridol, olomoucine or roscovitine) of 
cell cycle protein kinase family, CDKs, demonstrate improved behavioral outcomes and increased 
neuronal survival in a series of CNS disease models such as AD (Copani et al., 2001; Jorda et al., 
2003; Verdaguer et al., 2004b), PD (Kruman and Schwartz, 2006), stroke (Osuga et al., 2000; Wang 
et al., 2002) and TBI (Hilton et al., 2008). All of these neuropathologies are believed to involve 
iGluR-mediated excitotoxicity and there is a literature suggesting inhibitors of CDKs are 
neuroprotective against excitotoxicity (Giardinia and Beart, 2002). Overall, our gene profiling 
indicate that oxidative stress and cell cycle re-entry are primary events taking place during iGluR 
overactivation in neurons and further support the “two-hit” hypothesis for excitotoxic neuronal cell 
death. More importantly, our study suggests that a combined therapeutic approach using drugs that 
salvage oxidative stress and prevent the onset of cell cycle may potentially delay death and provide 
neurons with “bonus” time for recovery during excitotoxicity associated with multiple 
neurodegenerative diseases.   
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8. Figure Legends 
 
Figure 1. Classification of individual iGluRs global transcriptomic profiles (passed microarray 
selection criteria: total numbers of genes showing expression at least 1.5 fold change in a minimum 
of one out of the three time-points (5h, 15h and 24h) and statistical examination using one-way 
ANOVA, p < 0.05 and Benjamini-Hochberg FDR) according to specific time-points and fold-change 
expression up/down-regulated.  
 
 
Figure 2. Bi-model global transcriptomic profile analysis of individual iGluRs agonists against Glu 
excitotoxic model. Venn diagrams demonstrating the number of gene probes common and mutually 
exclusive to both models [A] Glu against NMDA [B] Glu against AMPA and [C] Glu against KA. 
 
 
Figure 3. Consistency in the transcriptional regulatory trend of the commonly occurring and 
significantly modulated gene probes in individual iGluRs against Glu excitotoxic models. 
 
Figure 4. Overall consistency in the transcriptional regulatory trend of the commonly occurring and 
significantly modulated gene probes [A] at respective time-points (5h, 15h and 24h) and [B] across 
all three time points in all four excitotoxic models. 
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9. Tables 
Table 1. Gene expression profiles of neuronal death-related families in cultured mouse primary cortical neurons treated with EC50 concentrations of AMPA, KA, 
NMDA and Glu over a 24-hour period respectively. All expression values (given as fold-changes) were selected based on having at least minimum of 1.5 fold 
change in at least one out of three time-points, subjected to one-way ANOVA analysis and were significant at p < 0.05. Values are given as mean  sem. 
 
 
Time-points 
300 µM AMPA 100 µM KA 200 µM NMDA 250 µM Glu 
Genbank Gene Title Symbol 5h 15h 24h 5h 15h 24h 5h 15h 24h 5h 15h 24h 
Calcium ion homeostasis and binding 
NM_008151 G-protein coupled receptor 12 Gpr12 
-2.40 
± 
0.09 
-1.70 
± 
0.15 
-1.80 
± 
0.14 
-2.18 
± 
0.13 
-2.66 
± 
0.12 
-2.89 
± 
0.11 
-1.50 
± 
0.19 
-2.20 
± 
0.11 
-2.00 
± 
0.13 
-1.43 
± 
0.19 
-1.80 
± 
0.17 
-1.40 
± 
0.18 
NM_007587 Calcitonin/calcitonin-related polypeptide, alpha Calca 
1.10 
± 
0.36 
1.50 
± 
0.47 
1.20 
± 
0.34 
1.11 
± 
0.40 
2.17 
± 
0.47 
2.15 
± 
0.67 
1.10 
± 
0.35 
1.90 
± 
0.54 
1.64 
± 
0.43 
-1.10 
± 
0.31 
2.30 
± 
0.66 
2.80 
± 
0.71 
NM_008855 Protein kinase C, beta 1 Prkcb 
-1.10 
± 
0.21 
-1.72 
± 
0.16 
-1.94 
± 
0.12 
-1.04 
± 
0.27 
-1.82 
± 
0.12 
-2.40 
± 
0.12 
-1.20 
± 
0.26 
-2.80 
± 
0.09 
-2.50 
± 
0.09 
-1.10 
± 
0.23 
-1.60 
± 
0.12 
-1.38 
± 
0.18 
NM_011313 S100 calcium binding protein A6 (calcyclin) S100a6 
1.17 
± 
0.23 
1.65 
± 
0.36 
1.10 
± 
0.19 
1.35 
± 
0.24 
2.12 
± 
0.39 
1.66 
± 
0.30 
1.50 
± 
0.29 
2.80 
± 
0.51 
2.22 
± 
0.35 
1.00 
± 
0.18 
1.93 
± 
0.38 
1.90 
± 
0.37 
NM_007585 Annexin A2 Anxa2 
1.99 
± 
0.38 
1.80 
± 
0.42 
1.38 
± 
0.31 
2.30 
± 
0.45 
1.98 
± 
0.34 
1.48 
± 
0.35 
1.90 
± 
0.38 
2.24 
± 
0.43 
1.60 
± 
0.31 
1.52 
± 
0.25 
1.93 
± 
0.31 
2.05 
± 
0.43 
NM_013470 Annexin A3 Anxa3 
1.30 
± 
0.30 
1.89 
± 
0.48 
1.66 
± 
0.58 
1.00 
± 
0.23 
1.95 
± 
0.43 
1.61 
± 
0.42 
1.50 
± 
0.45 
3.14 
 ± 
0.77 
2.60 
± 
0.58 
1.20 
± 
0.31 
3.60 
± 
0.81 
3.20 
± 
0.63 
NM_009673 Annexin A5 Anxa5 
-1.00 
± 
0.23 
1.50 
± 
0.31 
1.10 
± 
0.24 
-1.00 
± 
0.19 
1.50 
± 
0.33 
1.10 
± 
0.21 
1.40 
± 
0.27 
2.00 
± 
0.40 
1.80 
± 
0.35 
1.20 
± 
0.20 
1.70 
± 
0.29 
1.60 
± 
0.38 
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 Time-points
300μM AMPA 100μM KA 200μM NMDA 250μM Glu
Genbank Gene Title Symbol 5h 15h 24h 5h 15h 24h 5h 15h 24h 5h 15h 24h 
Lysosomal stress 
NM_017372 Lysozyme 2 Lyz2 
1.63 
± 
0.40 
1.42 
± 
0.36 
-1.13 
± 
0.24 
-1.10 
± 
0.29 
1.50 
± 
0.36 
1.40 
± 
0.43 
1.60 
± 
0.61 
2.10 
± 
0.69 
2.10 
± 
0.48 
1.20 
± 
0.30 
1.65 
± 
0.40 
1.50 
± 
0.44 
NM_010686 Lysosomal-associated protein transmembrane 5 Laptm5 
1.70 
± 
0.31 
1.40 
± 
0.34 
-1.10 
± 
0.19 
-1.50 
± 
0.18 
1.80 
± 
0.34 
1.40 
± 
0.50 
1.71 
± 
0.46 
2.31 
± 
0.98 
2.13 
± 
0.34 
1.34 
± 
0.25 
1.98 
± 
0.37 
1.95 
± 
0.40 
NM_010685 Lysosomal-associated membrane protein 2 Lamp2 
1.38 
± 
0.39 
1.60 
± 
0.41 
1.30 
± 
0.32 
1.63 
± 
0.39 
2.23 
± 
0.50 
1.54 
± 
0.37 
1.44  
± 
0.36 
2.31 
± 
0.41 
1.77 
± 
0.30 
-1.10 
± 
0.30 
1.75 
± 
0.51 
1.70 
± 
0.38 
NM_019972 Sortilin 1 Sort1 
1.10 
± 
0.35 
1.28 
± 
0.50 
1.22 
± 
0.54 
1.50 
± 
0.51 
2.31 
± 
0.56 
1.80 
± 
0.46 
1.50 
± 
0.45 
3.70 
± 
0.81 
2.50 
± 
0.64 
1.50 
± 
0.45 
2..00 
± 
0.63 
1.40 
± 
0.44 
NM_009906 Tripeptidyl peptidase I Tpp1 
1.20 
± 
0.29 
1.70 
± 
0.53 
1.10 
± 
0.30 
1.50 
± 
0.40 
1.95 
± 
0.53 
1.70 
± 
0.54 
1.20 
± 
0.36 
1.70 
± 
0.40 
1.30 
± 
0.31 
-1.10 
± 
0.32 
1.60 
± 
0.41 
1.60 
± 
0.40 
Anti-oxidant response - Heat shock proteins and molecular chaperones 
NM_010442 Heme oxygenase (decycling) 1 Hmox1 
2.32 
± 
0.45 
1.68 
± 
0.29 
1.38 
± 
0.51 
2.34 
± 
0.39 
2.17 
± 
0.39 
2.04 
± 
0.37 
2.70 
± 
0.58 
3.11 
± 
0.48 
1.60 
± 
0.29 
1.60 
± 
0.34 
2.37 
± 
0.41 
1.51 
± 
0.38 
NM_029688 Sulfiredoxin 1 homolog (S. cerevisiae) Srxn1 
2.60 
± 
0.56 
1.70 
± 
0.34 
1.30 
± 
0.41 
3.10 
± 
0.54 
1.93 
± 
0.36 
1.38 
± 
0.30 
2.00 
± 
0.39 
1.95 
± 
0.28 
1.10 
± 
0.19 
-1.20 
± 
0.29 
2.16 
± 
0.73 
1.17 
± 
0.43 
NM_007453 Peroxiredoxin 6 Prdx6 
1.32 
± 
0.41 
1.72 
± 
0.55 
1.16 
± 
0.37 
1.10 
± 
0.30 
1.30 
± 
0.30 
1.25 
± 
0.40 
1.14 
± 
0.36 
1.62 
± 
0.47 
1.20 
± 
0.28 
-1.10 
± 
0.27 
2.02 
± 
0.60 
1.80 
± 
0.56 
NM_008301 Heat shock protein 2 Hspa2 
1.50 
± 
0.44 
3.00 
± 
0.76 
2.30 
± 
0.64 
1.64 
± 
0.44 
2.77 
± 
0.65 
2.26 
± 
0.64 
1.00 
± 
0.26 
2.00 
± 
0.52 
2.00 
± 
0.47 
-1.30 
± 
0.19 
1.64 
± 
0.36 
1.60 
± 
0.39 
NM_030704 Heat shock protein 8 Hspb8 
1.80 
± 
0.45 
2.20 
± 
0.63 
1.40 
± 
0.59 
1.42 
± 
0.37 
2.61 
± 
0.59 
1.60 
± 
0.38 
2.00 
± 
0.46 
3.90 
± 
0.80 
1.83 
± 
0.46 
1.29 
± 
0.31 
4.40 
± 
1.06 
2.63 
± 
0.70 
NM_013602 Metallothionein 1 Mt1 
1.56 
± 
0.28 
1.74 
± 
0.28 
1.21 
± 
0.17 
2.00 
± 
0.40 
2.29 
± 
0.38 
1.92 
± 
0.38 
1.60 
± 
0.25 
2.00 
± 
0.34 
1.50 
± 
0.24 
1.10 
± 
0.16 
1.80 
± 
0.26 
1.80 
± 
0.39 
NM_013603 Metallothionein 3 Mt3 
1.49 
± 
0.26 
1.80 
± 
0.69 
1.10 
± 
0.20 
2.34 
± 
0.48 
1.90 
± 
0.34 
2.00 
± 
0.49 
1.35 
± 
0.27 
1.90 
± 
0.27 
1.80 
± 
0.55 
-1.10 
± 
0.17 
1.60 
± 
0.28 
1.60 
± 
0.30 
34 
 Time-points
300μM AMPA 100μM KA 200μM NMDA 250μM Glu
Genbank Gene Title Symbol 5h 15h 24h 5h 15h 24h 5h 15h 24h 5h 15h 24h 
Anti-oxidant response - Glutathione metabolism 
NM_010357 Glutathione S-transferase, alpha 4 Gsta4 
1.10 
± 
0.29 
1.82 
± 
0.44 
1.40 
± 
0.33 
1.14 
± 
0.31 
2.30 
± 
0.60 
2.03 
± 
0.48 
1.30 
± 
0.39 
3.05 
± 
0.70 
2.14 
± 
0.52 
-1.20 
± 
0.18 
2.60 
± 
0.63 
2.10 
± 
0.59 
NM_008184 Glutathione S-transferase, mu 6 Gstm6 
1.20 
± 
0.40 
1.50 
± 
0.53 
-1.00 
± 
0.35 
1.50 
± 
0.50 
1.90 
± 
0.52 
1.20 
± 
0.36 
1.45 
± 
0.45 
2.10 
± 
0.63 
1.34 
± 
0.35 
-1.20 
± 
0.22 
2.10 
± 
0.58 
1.70 
± 
0.52 
NM_019946 Microsomal glutathione S-transferase 1 Mgst1 
1.10 
± 
0.30 
1.80 
± 
0.46 
1.30 
± 
0.42 
1.40 
± 
0.44 
2.55 
± 
0.53 
1.91 
± 
0.51 
1.71 
± 
0.42 
2.96 
± 
0.60 
1.67 
± 
0.37 
-1.00 
± 
0.27 
3.20 
± 
0.87 
2.90 
± 
0.90 
NM_025569 Microsomal glutathione S-transferase 3 Mgst3 
-1.25 
± 
0.19 
-1.56 
± 
0.15 
-1.40 
± 
0.16 
-1.20 
± 
0.20 
-2.26 
± 
0.09 
-2.14 
± 
0.12 
-1.25 
± 
0.18 
-2.00 
± 
0.10 
-1.63 
± 
0.12 
-1.30 
± 
0.14 
-1.70 
± 
0.11 
-1.60 
± 
0.12 
NM_010358 Glutathione S-transferase, mu 1 Gstm1 
1.30 
± 
0.26 
1.68 
± 
0.27 
1.10 
± 
0.18 
1.57 
± 
0.33 
2.12 
± 
0.40 
1.42 
± 
0.40 
1.45 
± 
0.32 
2.23 
± 
0.46 
1.43 
± 
0.30 
-1.10 
± 
0.14 
1.90 
± 
0.37 
1.64 
± 
0.35 
Cell death 
NM_020581 Angiopoietin-like 4 Angptl4 
2.70 
± 
0.59 
5.32 
± 
1.14 
2.36 
± 
0.63 
4.74 
± 
0.84 
11.98 
± 
2.14 
10.21 
± 
2.28 
3.42 
± 
0.65 
7.93 
± 
1.61 
5.32 
± 
1.00 
2.00 
± 
0.46 
8.27 
± 
1.62 
8.24 
± 
1.58 
NM_009811 Caspase 6 Casp6 
1.10 
± 
0.28 
1.60 
± 
0.33 
1.20 
± 
0.32 
1.30 
± 
0.30 
2.10 
± 
0.35 
1.60 
± 
0.36 
1.50 
± 
0.39 
2.42 
± 
0.48 
1.74 
± 
0.27 
1.20 
± 
0.31 
2.00 
± 
0.37 
1.70 
± 
0.46 
NM_009818 Catenin (cadherin associated protein), alpha 1 Ctnna1 
1.30 
± 
0.21 
1.55 
± 
0.24 
1.20 
± 
0.18 
1.30 
± 
0.23 
2.10 
± 
0.29 
1.43 
± 
0.27 
1.55 
± 
0.28 
2.40 
± 
0.33 
1.80 
± 
0.32 
1.20 
± 
0.20 
1.90 
± 
0.34 
1.80 
± 
0.36 
NM_021399 B-cell leukemia/lymphoma 11B Bcl11b 
-1.07 
± 
0.17 
-1.80 
± 
0.11 
-1.60 
± 
0.12 
-1.37 
± 
0.16 
-1.53 
± 
0.12 
-1.82 
± 
0.11 
-1.00 
± 
0.21 
-2.20 
± 
0.09 
-1.80 
± 
0.11 
1.00 
± 
0.17 
-1.70 
± 
0.10 
-1.50 
± 
0.12 
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 Time-points
300μM AMPA 100μM KA 200μM NMDA 250μM Glu
Genbank Gene Title Symbol 5h 15h 24h 5h 15h 24h 5h 15h 24h 5h 15h 24h 
Cell homeostasis, survival and proliferation 
NM_010835 Homeobox, msh-like 1 Msx1 
1.17 
± 
0.35 
1.65 
± 
0.48 
1.00 
± 
0.29 
1.90 
± 
0.63 
2.02 
± 
0.54 
1.82 
± 
0.46 
1.25 
± 
0.33 
1.60 
± 
0.34 
1.45 
± 
0.36 
-1.30 
± 
0.25 
1.90 
± 
0.57 
1.80 
± 
0.47 
NM_152229 Nuclear receptor subfamily 2, group E, member 1 Nr2e1 
1.40 
± 
0.28 
1.80 
± 
0.38 
1.30 
± 
0.29 
1.90 
± 
0.40 
2.30 
± 
0.42 
1.70 
± 
0.35 
1.40 
± 
0.35 
2.00 
± 
0.32 
1.60 
± 
0.50 
1.00 
± 
0.21 
2.00 
± 
0.48 
2.10 
± 
0.47 
NM_009263 Secreted phosphoprotein 1 Spp1 
1.77 
± 
0.40 
1.55 
± 
0.38 
1.03 
± 
0.28 
-1.00 
± 
0.32 
2.43 
± 
0.68 
2.23 
± 
0.67 
1.90 
± 
0.83 
3.50 
± 
3.20 
4.30 
± 
1.17 
1.20 
± 
0.30 
2.00 
± 
0.44 
2.00 
± 
0.45 
NM_009129 Secretogranin II Scg2 
10.12 
± 
2.32 
11.74 
± 
2.39 
9.17 
± 
1.77 
11.00 
± 
2.47 
14.06 
± 
2.73 
12.03 
± 
1.93 
1.94 
± 
0.44 
2.44 
± 
0.82 
4.03 
± 
0.85 
1.00 
± 
0.22 
-4.09 
± 
0.07 
-3.79 
± 
0.08 
NM_009696 Apolipoprotein E Apoe 
1.09 
± 
0.23 
1.70 
± 
0.29 
1.30 
± 
0.24 
1.30 
± 
0.28 
2.36 
± 
0.43 
1.98 
± 
0.36 
1.15 
± 
0.27 
2.40 
± 
0.52 
1.80 
± 
0.27 
-1.20 
± 
0.14 
1.70 
± 
0.32 
1.70 
± 
0.37 
NM_009689 Baculoviral IAP repeat-containing 5 Birc5 
1.94 
± 
0.50 
1.25 
± 
0.37 
-1.00 
± 
0.26 
2.09 
± 
0.59 
1.39 
± 
0.35 
1.21 
± 
0.31 
2.00 
± 
0.56 
1.40 
± 
0.33 
-1.00 
± 
0.22 
1.54 
± 
0.36 
1.88 
± 
0.50 
1.34 
± 
0.30 
NM_013863 Bcl2-associated athanogene 3 Bag3 
1.80 
± 
0.24 
2.40 
± 
0.39 
2.40 
± 
0.48 
2.50 
± 
0.37 
2.49 
± 
0.37 
2.09 
± 
0.31 
2.30 
± 
0.47 
2.70 
± 
0.36 
2.50 
± 
0.48 
1.60 
± 
0.34 
2.00 
± 
0.38 
1.80 
± 
0.45 
NM_010514 Insulin-like growth factor 2 Igf2 
1.40 
± 
0.28 
1.50 
± 
0.30 
1.00 
± 
0.21 
1.80 
± 
0.35 
2.10 
± 
0.43 
1.60 
± 
0.39 
1.60 
± 
0.36 
1.70 
± 
0.41 
1.30 
± 
0.28 
1.60 
± 
0.32 
2.40 
± 
0.52 
2.10 
± 
0.52 
NM_133662 Immediate early response 3 Ier3 
1.40 
± 
0.32 
1.40 
± 
0.37 
1.80 
± 
0.45 
-1.00 
± 
0.26 
1.60 
± 
0.31 
1.60 
± 
0.35 
1.20 
± 
0.32 
1.70 
± 
0.31 
1.60 
± 
0.27 
1.90 
± 
0.48 
1.10 
± 
0.34 
1.00 
± 
0.21 
NM_008520 Latent transforming growth factor beta binding protein 3 Ltbp3 
1.10 
± 
0.25 
1.80 
± 
0.43 
1.60 
± 
0.32 
1.05 
± 
0.33 
1.23 
± 
0.41 
1.38 
± 
0.41 
1.20 
± 
0.26 
1.60 
± 
0.34 
1.80 
± 
0.35 
-1.00 
± 
0.22 
1.50 
± 
0.25 
1.90 
± 
0.41 
NM_010518 Insulin-like growth factor binding protein 5 Igfbp5 
-1.10 
± 
0.25 
1.60 
± 
0.32 
1.10 
± 
0.26 
1.30 
± 
0.26 
2.14 
± 
0.38 
1.61 
± 
0.40 
1.10 
± 
0.25 
2.00 
± 
0.40 
1.80 
± 
0.39 
-1.20 
± 
0.12 
1.70 
± 
0.28 
1.90 
± 
0.40 
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 Time-points
300μM AMPA 100μM KA 200μM NMDA 250μM Glu
Genbank Gene Title Symbol 5h 15h 24h 5h 15h 24h 5h 15h 24h 5h 15h 24h 
NM_021099 Kit oncogene Kit 
-2.12 
± 
0.10 
-1.19 
± 
0.20 
-1.15 
± 
0.18 
-1.84 
± 
0.11 
-2.90 
± 
0.07 
-2.40 
± 
0.10 
-1.50 
±  
0.13 
-2.10 
± 
0.10 
-1.20 
± 
0.18 
-1.50 
± 
0.12 
-1.70 
± 
0.12 
-1.50 
± 
0.17 
Mitotic cell cycle 
NM_025565 
SPC25, NDC80 kinetochore 
complex component, 
homolog (S. cerevisiae) 
Spc25 
1.79 
± 
0.52 
1.50 
± 
0.52 
-1.08 
± 
0.32 
2.40 
± 
0.81 
1.83 
± 
0.57 
1.34 
± 
0.45 
2.11 
± 
0.48 
1.82 
± 
0.49 
1.21 
± 
0.32 
1.66 
± 
0.41 
1.85 
± 
0.65 
1.47 
± 
0.63 
NM_028390 Anillin, actin binding protein Anln 
1.97 
± 
0.51 
1.28 
± 
0.28 
-1.10 
± 
0.19 
1.96 
± 
0.48 
1.60 
± 
0.35 
1.19 
± 
0.32 
1.84 
± 
0.41 
1.50 
± 
0.33 
1.18 
± 
0.26 
1.80 
± 
0.40 
1.86 
± 
0.51 
1.67 
± 
0.41 
NM_011497 Aurora kinase A Aurka 
2.31 
± 
0.56 
1.48 
± 
0.36 
1.04 
± 
0.25 
2.30 
± 
0.55 
1.46 
± 
0.37 
1.07 
± 
0.29 
1.65 
± 
0.40 
1.31 
± 
0.32 
1.11 
± 
0.26 
1.91 
± 
0.42 
1.98 
± 
0.50 
1.59 
± 
0.44 
NM_028109 
TPX2, microtubule-
associated protein homolog 
(Xenopus laevis) 
Tpx2 
1.80 
± 
0.46 
1.27 
± 
0.41 
-1.08 
± 
0.26 
1.90 
± 
0.49 
1.49 
± 
0.45 
1.06 
± 
0.35 
1.80 
± 
0.49 
1.50 
± 
0.33 
1.10 
± 
0.25 
1.70 
± 
0.42 
2.09 
± 
0.55 
1.57 
± 
0.46 
NM_007659 Cyclin-dependent kinase 1 Cdk1 
2.58 
± 
0.62 
1.54 
± 
0.45 
-1.10 
± 
0.26 
3.02 
± 
0.71 
1.74 
± 
0.38 
1.18 
± 
0.32 
2.10 
± 
0.51 
1.66 
± 
0.39 
1.19 
± 
0.26 
2.06 
± 
0.42 
1.91 
± 
0.47 
1.50 
± 
0.39 
NM_023223 Cell division cycle 20 homolog (S. cerevisiae) Cdc20 
1.53 
± 
0.50 
1.06 
± 
0.38 
-1.15 
± 
0.24 
1.51 
± 
0.55 
1.35 
± 
0.50 
1.04 
± 
0.46 
1.87 
± 
0.39 
1.43 
± 
0.31 
-1.02 
± 
0.24 
1.61 
± 
0.41 
2.03 
± 
0.50 
1.32 
± 
0.36 
NM_013538 Cell division cycle associated 3 Cdca3 
2.17 
± 
0.65 
1.45 
± 
0.45 
1.00 
± 
0.28 
1.94 
± 
0.55 
1.96 
± 
0.56 
1.34 
± 
0.41 
2.18 
± 
0.62 
1.78 
± 
0.42 
1.04 
± 
0.26 
1.57 
± 
0.39 
2.03 
± 
0.48 
1.43 
± 
0.39 
NM_172301 Cyclin B1 Ccnb1 
2.75 
± 
0.63 
1.66 
± 
0.40 
1.00 
± 
0.30 
3.13 
± 
0.82 
1.85 
± 
0.60 
1.42 
± 
0.43 
2.07 
± 
0.50 
1.62 
± 
0.41 
1.19 
± 
0.29 
1.68 
± 
0.42 
2.09 
± 
0.54 
1.48 
± 
0.51 
NM_009831 Cyclin G1 Ccng1 
1.30 
± 
0.32 
1.47 
± 
0.49 
1.12 
± 
0.23 
1.53 
± 
0.47 
1.35 
± 
0.36 
-1.01 
± 
0.27 
1.30 
± 
0.34 
1.55 
± 
0.33 
1.25 
± 
0.34 
1.36 
± 
0.31 
1.52 
± 
0.39 
1.31 
± 
0.29 
NM_031166 Inhibitor of DNA binding 4 Id4 
1.27 
± 
0.38 
1.65 
± 
0.48 
1.07 
± 
0.28 
1.57 
± 
0.47 
2.20 
± 
0.65 
1.70 
± 
0.59 
1.36 
± 
0.41 
1.89 
± 
0.53 
1.15 
± 
0.34 
-1.41 
± 
0.21 
1.93 
± 
0.56 
2.11 
± 
0.76 
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 Time-points
300μM AMPA 100μM KA 200μM NMDA 250μM Glu
Genbank Gene Title Symbol 5h 15h 24h 5h 15h 24h 5h 15h 24h 5h 15h 24h 
NM_010578 Integrin beta 1 (fibronectin receptor beta) Itgb1 
1.58 
± 
0.33 
1.29 
± 
0.23 
1.13 
± 
0.22 
1.59 
± 
0.30 
1.64 
± 
0.31 
1.13 
± 
0.23 
1.54 
± 
0.31 
1.45 
± 
0.29 
1.10 
± 
0.20 
1.34 
± 
0.22 
1.64 
± 
0.28 
1.46 
± 
0.32 
NM_023317 Nuclear distribution gene E homolog 1 (A nidulans) Nde1 
1.40 
± 
0.39 
1.74 
± 
0.45 
1.11 
± 
0.27 
1.58 
± 
0.42 
1.89 
± 
0.47 
1.57 
± 
0.45 
1.28 
± 
0.32 
1.56 
± 
0.35 
1.24 
± 
0.30 
1.13 
± 
0.30 
1.77 
± 
0.43 
1.35 
± 
0.35 
NM_007595 
Calcium/calmodulin-
dependent protein kinase II, 
beta 
Camk2b 
-1.04 
± 
0.16 
-1.57 
± 
0.13 
-1.52 
± 
0.11 
1.00 
± 
0.16 
-2.10 
± 
0.08 
-2.30 
± 
0.10 
-1.31 
± 
0.13 
-2.47 
± 
0.06 
-1.71 
± 
0.11 
-1.18 
± 
0.13 
-2.33 
± 
0.09 
-1.74 
± 
0.11 
NM_008913 
Protein phosphatase 3, 
catalytic subunit, alpha 
isoform 
Ppp3ca 
1.00 
± 
0.23 
-1.45 
± 
0.25 
-1.93 
± 
0.09 
1.41 
± 
0.25 
-1.74 
± 
0.10 
-2.12 
± 
0.10 
-1.00 
± 
0.23 
-2.14 
± 
0.09 
-1.82 
± 
0.21 
1.03 
± 
0.20 
-1.71 
± 
0.11 
-1.48 
± 
0.12 
NM_023396 Reprimo, TP53 dependent G2 arrest mediator candidate Rprm 
-1.30 
± 
0.15 
-1.44 
± 
0.16 
-1.52 
± 
0.13 
-1.40 
± 
0.17 
-1.80 
± 
0.12 
-1.80 
± 
0.11 
-1.15 
± 
0.18 
-1.80 
± 
0.10 
-1.60 
± 
0.10 
1.00 
± 
0.18 
-2.00 
± 
0.09 
-1.90 
± 
0.11 
38 
Table 2. Genes encoding for proteins involved in mitotic cell division in individual excitotoxicity global transcriptomic profiles. Genes were selected on the basis of 
demonstrating at least ±1.5 fold-change expression in at least one out of three time-points (5h, 15h and 24h) and passed statistical testing of one-way ANOVA, p 
<0.05 and FDR correction. The genes were classified in the table according to the first time-point where significant regulation above or below 1.5 is detected. 
 
 300μM AMPA 200μM NMDA 100μM KA 250μM Glu 
Up-regulation 
(5h) 
 
Continue … 
 Anillin, actin binding protein 
 Aurora kinase A 
 baculoviral IAP repeat-
containing 5 
 Buninhibited by 
benzimidazoles 1 homolog, 
beta (S. cerevisiae) 
 Cyclin-dependent kinase 1 
 cell division cycle 20 homolog 
(S. cerevisiae) 
 cell division cycle associated 2 
 cell division cycle associated 3 
 cell division cycle associated 5 
 cyclin D1 
 cyclin D2 
 DBF4 homolog (S. cerevisiae) 
 E4F transcription factor 1 
 integrin beta 1 (fibronectin 
receptor beta) 
 neural precursor cell 
expressed, developmentally 
down-regulated gene 9 
 non-SMC condensin I 
complex, subunit H 
 polo-like kinase 1 (Drosophila) 
 predicted gene 8416; predicted 
gene 5593; cyclin B1; similar 
to cyclin B1; predicted gene 
4870 
 regulator of chromosome 
condensation 2; hypothetical 
protein LOC100047340 
 
 Anillin, actin binding protein 
 Aurora kinase A 
 Baculoviral IAP repeat-
containing 5 
 Budding uninhibited by 
benzimidazoles 1 homolog, beta 
(S. cerevisiae) 
 Cyclin-dependent kinase 1 
 Cell division cycle 20 homolog 
(S. cerevisiae) 
 Cell division cycle associated 2 
 Cell division cycle associated 3 
 Cell division cycle associated 5 
 Cell division cycle associated 8 
 Cyclin B1 
 Cyclin-dependent kinase 2 
 DBF4 homolog (S. cerevisiae) 
 Integrin beta 1 (fibronectin 
receptor beta) 
 Kinesin family member C1  
 MAD2 mitotic arrest deficient-
like 1 (yeast) 
 Microtubule-associated protein, 
RP/EB family, member 2 
 Neural precursor cell expressed, 
developmentally down-regulated 
gene 1 
 Non-SMC condensin I complex, 
subunit H 
 Nucleolar and spindle associated 
protein 1 
 Pituitary tumor-transforming 
gene 1 
 Anillin, actin binding protein 
 Asp (abnormal spindle)-like, 
microcephaly associated 
(Drosophila) 
 AT hook containing 
transcription factor 1 
 Aurora kinase A 
 Baculoviral IAP repeat-
containing 5 
 Budding uninhibited by 
benzimidazoles 1 homolog, 
beta (S. cerevisiae) 
 Cyclin-dependent kinase 1 
 Cell division cycle 20 homolog 
(S. cerevisiae) 
 Cell division cycle 6 homolog 
(S. cerevisiae);  
 Cell division cycle associated 3 
 Cell division cycle associated 5 
 Coiled-coil domain containing 
99 
 Cyclin D1 
 Cyclin D2 
 Cyclin G1 
 Cyclin B1 
 Cyclin-dependent kinase 2 
 DBF4 homolog (S. cerevisiae) 
 E4F transcription factor 1 
 Inhibitor of DNA binding 4 
 Integrin beta 1 (fibronectin 
receptor beta) 
 
 
 Anillin, actin binding protein 
 Aurora kinase A 
 Baculoviral IAP repeat-
containing 5 
 Cyclin B1 
 Cyclin-dependent kinase 1 
 Cell division cycle associated 2 
 Cell division cycle associated 3 
 Cell division cycle associated 5 
 Cell division cycle associated 8 
 E4F transcription factor 1 
 Nucleolar and spindle associated 
protein 1 
 Polo-like kinase 1 (Drosophila) 
 Pescadillo homolog 1, 
containing BRCT domain 
(zebrafish) 
 SPC24, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
 SPC25, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
 Sperm associated antigen 5 
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 300μM AMPA 200μM NMDA 100μM KA 250μM Glu 
Up-regulation 
(5h) 
 
 
 SPC25, NDC80 kinetochore  
complex component, homolog 
(S. cerevisiae) 
 Polo-like kinase 1 (Drosophila) 
 SPC24, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
 SPC25, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
 Sperm associated antigen 5 
 Microtubule-associated protein, 
RP/EB family, member 2 
 Neural precursor cell expressed, 
developmentally down-
regulated gene 9 
 Non-SMC condensin II 
complex, subunit G2 
 Nuclear distribution gene E 
homolog 1 (A nidulans) 
 Nucleolar and spindle 
associated protein 1 
 ribosomal protein S6 
 SET domain containing (lysine 
methyltransferase) 8 
 Kinesin family member C1 
 MAD2 mitotic arrest deficient-
like 1 (yeast) 
 SPC25, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
 sperm associated antigen 5 
 
 
Down-
regulation at 
5h 
 NIMA (never in mitosis gene 
a)-related expressed kinase 3 
 Calcium/calmodulin-dependent 
protein kinase II alpha 
 CDK5 and Abl enzyme 
substrate 1 
 NIMA (never in mitosis gene 
a)-related expressed kinase 3 
 SAC3 domain containing 1 
 tubulin, gamma 1 
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 300μM AMPA 200μM NMDA 100μM KA 250μM Glu 
Up-regulation 
at 15h 
 Calcium/calmodulin-
dependent protein kinase II, 
delta 
 Cyclin G1 
 Inhibitor of DNA binding 4 
 Nuclear distribution gene E 
homolog 1 (A nidulans) 
 Nucleolar and spindle 
associated protein 1 
 
 Cyclin G1 
 E2F transcription factor 6 
 Inhibitor of DNA binding 4 
 MAD2 mitotic arrest deficient-
like 2 (yeast) 
 Nuclear distribution gene E 
homolog 1 (A nidulans) 
 Anaphase promoting complex 
subunit 1 
 Neural precursor cell expressed, 
developmentally down-
regulated gene 1 
 Cell division cycle 20 homolog 
(S. cerevisiae) 
 Cyclin G1 
 E2F transcription factor 6 
 Inhibitor of DNA binding 4 
 Integrin beta 1 (fibronectin 
receptor beta) 
 Neural precursor cell expressed, 
developmentally down-regulated 
gene 1 
 Non-SMC condensin I complex, 
subunit H 
 Nuclear distribution gene E 
homolog 1 (A nidulans) 
 Nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent 1 
 Pituitary tumor-transforming 
gene 1 
Down-
regulation at 
15h 
 Calcium/calmodulin-
dependent protein kinase II, 
beta 
 Tubulin, beta 3 
 Calcium/calmodulin-dependent 
protein kinase II, beta 
 Cyclin D1 
 Fibronectin type 3 and SPRY 
domain-containing protein 
 Protein phosphatase 3, catalytic 
subunit, alpha isoform 
 Ras homolog gene family, 
member U 
 Stathmin 1 
 Tubulin, beta 3 
 Budding uninhibited by 
benzimidazoles 3 homolog (S. 
cerevisiae) 
 Calcium/calmodulin-dependent 
protein kinase II alpha 
 Calcium/calmodulin-dependent 
protein kinase II, beta 
 Protein phosphatase 3, catalytic 
subunit, alpha isoform 
 Ras homolog gene family, 
member U 
 Regulator of chromosome 
condensation 2; hypothetical 
protein LOC100047340 
 Calcium/calmodulin-dependent 
protein kinase II gamma gamma 
 Stathmin 1 
 
 Amyloid beta (A4) precursor 
protein 
 Calcium/calmodulin-dependent 
protein kinase II alpha 
 Calcium/calmodulin-dependent 
protein kinase II, beta 
 Microtubule-associated protein, 
RP/EB family, member 2 
 Polo-like kinase 2 (Drosophila) 
 Protein phosphatase 3, catalytic 
subunit, alpha isoform 
 Ras homolog gene family, 
member U 
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 300μM AMPA 200μM NMDA 100μM KA 250μM Glu 
Down-
regulation at 
24h 
 Centrin 2 
 Protein phosphatase 3, 
catalytic subunit, alpha 
isoform 
 Tubulin, gamma 1  ADP-ribosylation factor-like 
8A 
 Activating transcription factor 6 
beta 
 Centrin 2 
 Centrin 3 
 Checkpoint with forkhead and 
ring finger domains 
 Chromatin modifying protein 
1A; predicted gene 8515 
 Thioredoxin-like 4B 
 Tubulin, beta 3 
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Table 3. Validation of microarray data using real-time PCR technique on mouse culture treated with 250 µM Glu. All fold-change 
expressions are statistically significant at p < 0.05. Data are expressed as mean  sem.  
 
 
GenBank 
 
Gene Title 
 
Symbol 
5h 15h 24h 
Microarray Real-time PCR Microarray 
Real-time 
PCR Microarray 
Real-time 
PCR 
NM_030704 Heat shock protein 8 Hspb8 1.29 ± 0.31 1.42 ± 0.69 4.40 ± 1.06 9.29 ± 0.55 2.63 ± 0.70 2.24 ± 0.72 
NM_010442 Heme oxygenase 1 Hmox1 1.59 ± 0.34  2.37 ± 0.41 1.78 ± 0.62 1.51 ± 0.38  
NM_029688 Sulfiredoxin 1 homolog Srxn1 -1.20 ± 0.29  2.16 ± 0.73 2.99 ± 0.55 1.17 ± 0.43  
NM_011121 Polo-like kinase 1 Plk1 2.08 ± 0.32  2.06 ± 0.37 1.64 ± 0.59 1.62 ± 0.30  
NM_007585 Annexin A2 AnxA2 1.52 ± 0.25  1.93 ± 0.31  2.05 ± 0.43 8.25 ± 0.61 
NM_020581 Angiopoietin-like 4 Angptl4 2.00 ± 0.46 3.28 ± 0.66 8.27 ± 1.62  8.24 ± 1.58 5.63 ± 0.58 
NM_011497 Aurora kinase A Aurka 1.91 ± 0.42 3.31 ± 0.69 1.98 ± 0.50 1.95 ± 0.72 1.59 ± 0.44 2.97 ± 1.11 
NM_028109 
TPX2, 
microtubule-
associated 
protein homolog 
Tpx2 1.70 ± 0.42  2.09 ± 0.55 4.79 ± 0.78 1.57 ± 0.46 4.21 ± 0.60 
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10. Supplementary data 
 
Supplementary table 1. Significantly expressed genes (with fold-change of at least 1.5 in a minimum one 
out of three time-points and passed One-way ANOVA, p<0.05) encoding for proteins involved in mitotic cell 
cycle upon 300μM AMPA-mediated excitotoxicity in cultured primary cortical neurons. Data are expressed as 
mean  sem.  
 
 300μM AMPA 
Genbank Title Symbol 5h 15h 24h 
Mitotic cell cycle 
NM_172301 Cyclin B1 Ccnb1 2.75 ± 0.63 1.66 ± 0.40 1.03 ± 0.30 
NM_007659 Cyclin-dependent kinase 1 Cdk1 2.58 ± 0.62 1.54 ± 0.45 -1.10 ± 0.26 
NM_011121 Polo-like kinase 1 (Drosophila) Plk1 2.40 ± 0.52 1.19 ± 0.42 -1.08 ± 0.20 
NM_013726 DBF4 homolog (S. cerevisiae) Dbf4 2.32 ± 0.55 1.76 ± 0.45 1.25 ± 0.35 
NM_011497 Aurora kinase A AurkA 2.31 ± 0.56 1.48 ± 0.36 1.04 ± 0.25 
NM_009829 Cyclin D2 Ccnd2 2.22 ± 0.61 1.50 ± 0.33 1.01 ± 0.18 
NM_013538 Cell division cycle associated 3 Cdca3 2.17 ± 0.65 1.45 ± 0.45 1.01 ± 0.28 
NM_009773 
Budding uninhibited by 
benzimidazoles 1 
homolog, beta (S. 
cerevisiae) 
Bub1b 2.15 ± 0.62 1.34 ± 0.54 -1.09 ± 0.26 
NM_028390 Anillin, actin binding protein Anln 1.97 ± 0.51 1.28 ± 0.28 -1.10 ± 0.19 
NM_009689 Baculoviral IAP repeat-containing 5 Birc5 1.94 ± 0.50 1.25 ± 0.37 -1.03 ± 0.26 
NM_175384 Cell division cycle associated 2 Cdca2 1.92 ± 0.42 1.12 ± 0.29 -1.12 ± 0.19 
NM_173867 Regulator of chromosome condensation 2 Rcc2 1.90 ± 0.59 1.92 ± 0.55 1.64 ± 0.47 
NM_026410 Cell division cycle associated 5 Cdca5 1.86 ± 0.38 1.10 ± 0.32 -1.21 ± 0.22 
NM_144818 Non-SMC condensin I complex, subunit H Ncaph 1.83 ± 0.69 1.32 ± 0.63 1.02 ± 0.46 
NM_025565 
SPC25, NDC80 
kinetochore complex 
component, homolog (S. 
cerevisiae) 
Spc25 1.79 ± 0.52 1.50 ± 0.52 -1.08 ± 0.32 
NM_017464 
Neural precursor cell 
expressed, 
developmentally down-
regulated gene 9 
Nedd9 1.72 ± 0.47 1.97 ± 0.56 1.31 ± 0.36 
NM_023223 Cell division cycle 20 homolog (S. cerevisiae) Cdc20 1.65 ± 0.52 1.14 ± 0.34 1.03 ± 0.33 
NM_010578 Integrin beta 1 (fibronectin receptor beta) Itgb1 1.58 ± 0.33 1.29 ± 0.23 1.13 ± 0.22 
NM_007893 E4F transcription factor 1 E4f1 1.53 ± 0.45 1.42 ± 0.41 1.28 ± 0.38 
NM_007631 Cyclin D1 Ccnd1 1.46 ± 0.45 -1.00 ± 0.25 -1.63 ± 0.18 
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NM_023317 Nuclear distribution gene E homolog 1 (A nidulans) Nde1 1.40 ± 0.39 1.74 ± 0.45 1.11 ± 0.27 
NM_009831 Cyclin G1 Ccng1 1.28 ± 0.32 1.58 ± 0.49 1.05 ± 0.23 
NM_023813 
Calcium/calmodulin-
dependent protein kinase 
II, delta 
Camk2d 1.28 ± 0.38 1.57 ± 0.41 1.24 ± 0.29 
NM_031166 Inhibitor of DNA binding 4 Id4 1.27 ± 0.38 1.65 ± 0.48 1.07 ± 0.28 
NM_008913 
Protein phosphatase 3, 
catalytic subunit, alpha 
isoform 
Ppp3ca 1.01 ± 0.23 -1.45 ± 0.25 -1.93 ± 0.09 
NM_007595 
Calcium/calmodulin-
dependent protein kinase 
II, beta 
Camk2b -1.04 ± 0.16 -1.56 ± 0.13 -1.52 ± 0.11 
NM_019405 Centrin 2 Cetn2 -1.07 ± 0.24 -1.33 ± 0.24 -1.83 ± 0.21 
NM_023279 Tubulin, beta 3 class III Tubb3 -1.39 ± 0.23 -1.82 ± 0.18 -1.75 ± 0.19 
NM_011848 
NIMA (never in mitosis 
gene a)-related expressed 
kinase 3 
Nek3 -1.78 ± 0.13 -1.12 ± 0.16 -1.30 ± 0.13 
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Supplementary table 2. Significantly expressed genes (with fold-change of at least 1.5 in a minimum one out 
of three time-points and passed One-way ANOVA, p<0.05) encoding for proteins involved in mitotic cell cycle 
upon 100μM KA-mediated excitotoxicity in cultured primary cortical neurons. Data are expressed as mean  
sem.  
 
 100μM KA 
Genbank Gene title Symbol 5h 15h 24h 
Mitotic cell cycle 
NM_172301 Cyclin B1 Ccnb1 3.13 ± 0.75 1.85 ± 0.39 1.42 ± 0.37 
NM_007659 Cyclin-dependent kinase 1 Cdk1 3.02 ± 0.71 1.74 ± 0.38 1.18 ± 0.32 
NM_013726 DBF4 homolog (S. cerevisiae) Dbf4 2.63 ± 0.59 1.76 ± 0.41 1.36 ± 0.32 
NM_025565 
SPC25, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
Spc25 2.38 ± 0.81 1.83 ± 0.57 1.34 ± 0.45 
NM_009773 
Budding uninhibited by 
benzimidazoles 1 homolog, 
beta (S. cerevisiae) 
Bub1b 2.33 ± 0.58 1.67 ± 0.50 1.27 ± 0.51 
NM_017464 
Neural precursor cell 
expressed, developmentally 
down-regulated gene 9 
Nedd9 2.31 ± 0.74 1.58 ± 0.48 1.38 ± 0.36 
NM_011497 Aurora kinase A AurkA 2.30 ± 0.55 1.46 ± 0.37 1.07 ± 0.29 
NM_023223 Cell division cycle 20 homolog (S. cerevisiae) Cdc20 1.51 ± 0.55 1.35 ± 0.50 1.04 ± 0.46 
NM_009829 Cyclin D2 Ccnd2 2.18 ± 0.33 1.26 ± 0.25 1.01 ± 0.34 
NM_009689 Baculoviral IAP repeat-containing 5 Birc5 2.09 ± 0.59 1.39 ± 0.35 1.21 ± 0.31 
NM_028390 Anillin, actin binding protein Anln 1.96 ± 0.48 1.60 ± 0.35 1.19 ± 0.32 
NM_009791 
Asp (abnormal spindle)-like, 
microcephaly associated 
(Drosophila) 
Aspm 1.95 ± 0.61 1.39 ± 0.45 1.22 ± 0.49 
NM_013538 Cell division cycle associated 3 Cdca3 1.94 ± 0.55 1.96 ± 0.56 1.34 ± 0.41 
NM_173867 Regulator of chromosome condensation 2 Rcc2 1.88 ± 0.64 2.00 ± 0.56 1.97 ± 0.51 
NM_053173 Kinesin family member C1 Kifc5a 1.88 ± 0.50 1.41 ± 0.38 1.17 ± 0.34 
NM_007893 E4F transcription factor 1 E4f1 1.84 ± 0.46 1.83 ± 0.47 1.91 ± 0.51 
NM_026410 Cell division cycle associated 5 Cdca5 1.82 ± 0.34 1.20 ± 0.30 -1.03 ± 0.23 
NM_009096 Ribosomal protein S6 Rps6 1.75 ± 0.45 1.29 ± 0.41 1.23 ± 0.47 
NM_133762 Non-SMC condensin II complex, subunit G2 Ncapg2 1.66 ± 0.45 1.17 ± 0.41 -1.03 ± 0.34 
NM_010578 Integrin beta 1 (fibronectin receptor beta) Itgb1 1.59 ± 0.30 1.64 ± 0.31 1.13 ± 0.23 
NM_023317 Nuclear distribution gene E homolog 1 (A nidulans) Nde1 1.58 ± 0.42 1.89 ± 0.47 1.57 ± 0.45 
NM_019499 MAD2 mitotic arrest deficient-like 1 (yeast) Mad2l1 1.58 ± 0.58 1.15 ± 0.41 -1.13 ± 0.40 
NM_017407 Sperm associated antigen 5 Spag5 1.57 ± 0.49 1.63 ± 0.39 1.10 ± 0.28 
NM_031166 Inhibitor of DNA binding 4 Id4 1.57 ± 0.47 2.19 ± 0.65 1.72 ± 0.59 
NM_016756 Cyclin-dependent kinase 2 Cdk2 1.55 ± 0.39 1.31 ± 0.29 1.16 ± 0.30 
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NM_026375 AT hook containing transcription factor 1 Ahctf1 1.55 ± 0.38 1.27 ± 0.29 1.07 ± 0.29 
NM_027411 Coiled-coil domain containing 99 Ccdc99 1.54 ± 0.52 1.10 ± 0.29 1.07 ± 0.38 
NM_011799 Cell division cycle 6 homolog (S. cerevisiae) Cdc6 1.53 ± 0.42 1.06 ± 0.27 1.10 ± 0.34 
NM_009831 Cyclin G1 Ccng1 1.53 ± 0.33 1.35 ± 0.25 -1.01 ± 0.22 
NM_007631 Cyclin D1 Ccnd1 1.51 ± 0.42 1.06 ± 0.31 -1.28 ± 0.24 
NM_030241 SET domain containing (lysine methyltransferase) 8 Setd8 1.51 ± 0.43 -1.07 ± 0.25 -1.14 ± 0.24 
NM_153058 
Microtubule-associated 
protein, RP/EB family, 
member 2 
Mapre2 1.50 ± 0.49 1.44 ± 0.42 1.08 ± 0.39 
NM_008682 
Neural precursor cell 
expressed, developmentally 
down-regulated gene 1 
Nedd1 1.43 ± 0.33 1.67 ± 0.33 1.23 ± 0.34 
NM_008913 
Protein phosphatase 3, 
catalytic subunit, alpha 
isoform 
Ppp3ca 1.41 ± 0.25 -1.74 ± 0.10 -2.12 ± 0.10 
NM_019641 Stathmin 1 Stmn1 1.40 ± 0.39 -2.29 ± 0.13 -1.60 ± 0.27 
NM_019405 Centrin 2 Cetn2 1.36 ± 0.39 -1.41 ± 0.23 -1.91 ± 0.17 
NM_009774 
Budding uninhibited by 
benzimidazoles 3 homolog (S. 
cerevisiae) 
Bub3 1.17 ± 0.31 -1.59 ± 0.14 -1.66 ± 0.16 
NM_007684 Centrin 3 Cetn3 1.16 ± 0.32 -1.25 ± 0.19 -1.61 ± 0.19 
NM_008569 Anaphase promoting complex subunit 1 Apc1 1.16 ± 0.25 1.61 ± 0.39 1.31 ± 0.35 
NM_026823 ADP-ribosylation factor-like 8A Arl8a 1.15 ± 0.23 -1.37 ± 0.18 -1.78 ± 0.14 
NM_145606 Chromatin modifying protein 1A Chmp1a 1.11 ± 0.26 -1.43 ± 0.13 -1.59 ± 0.12 
NM_178597 
Calcium/calmodulin-
dependent protein kinase type 
II gamma chain  
Camkg 1.10 ± 0.24 -1.69 ± 0.12 -1.71 ± 0.17 
NM_007595 
Calcium/calmodulin-
dependent protein kinase II, 
beta 
Camk2b 1.01 ± 0.16 -2.09 ± 0.08 -2.25 ± 0.10 
NM_017406 Activating transcription factor 6 beta Atf6b -1.01 ± 0.21 -1.38 ± 0.14 -1.76 ± 0.14 
NM_023279 Tubulin, beta 3 class III Tubb3 -1.13 ± 0.33 -2.22 ± 0.15 -2.58 ± 0.13 
NM_177407 
Calcium/calmodulin-
dependent protein kinase II 
alpha 
Camk2a -1.15 ± 0.31 -1.62 ± 0.20 -1.54 ± 0.20 
NM_172717 Checkpoint with forkhead and ring finger domains Chfr -1.16 ± 0.30 -1.42 ± 0.25 -1.67 ± 0.22 
NM_133955 Ras homolog gene family, member U Rhou -1.32 ± 0.16 -1.98 ± 0.10 -2.18 ± 0.09 
NM_175646 Thioredoxin-like 4B Txnl4b -1.41 ± 0.21 -1.29 ± 0.20 -1.68 ± 0.16 
NM_022021 CDK5 and Abl enzyme substrate 1 Cables1 -1.56 ± 0.14 -1.87 ± 0.12 -2.11 ± 0.12 
NM_133678 SAC3 domain containing 1 Sac3d1 -1.58 ± 0.26 -1.55 ± 0.23 -1.80 ± 0.17 
NM_134024 Tubulin, gamma 1 Tubg -1.66 ± 0.13 -1.52 ± 0.13 -1.70 ± 0.15 
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NM_011848 NIMA (never in mitosis gene a)-related expressed kinase 3 Nek3 -1.79 ± 0.14 -1.20 ± 0.17 -1.68 ± 0.13 
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Supplementary table 3.  Significantly expressed genes (with fold-change of at least 1.5 in a minimum 
one out of three time-points and passed One-way ANOVA, p<0.05) encoding for proteins involved in 
mitotic cell cycle upon 200μM NMDA-mediated excitotoxicity in cultured primary cortical neurons. Data 
are expressed as mean  sem.  
 
 200μM NMDA 
Genbank Genbank Symbol 5h 15h 24h 
Mitotic cell cycle 
NM_013538 Cell division cycle associated 3 Cdca3 2.18 ± 0.62 1.78 ± 0.42 1.04 ± 0.26 
NM_025565 
SPC25, NDC80 kinetochore 
complex component, 
homolog (S. cerevisiae) 
Spc25 2.11 ± 0.48 1.82 ± 0.49 1.21 ± 0.32 
NM_007659 Cyclin-dependent kinase 1 Cdk1 2.10 ± 0.51 1.66 ± 0.39 1.20 ± 0.26 
NM_172301 Cyclin B1 Ccnb1 2.07 ± 0.50 1.62 ± 0.41 1.19 ± 0.29 
NM_009689 Baculoviral IAP repeat-containing 5 Birc5 1.96 ± 0.56 1.41 ± 0.33 -1.02 ± 0.22 
NM_011121 Polo-like kinase 1 (Drosophila) Plk1 1.90 ± 0.38 1.44 ± 0.21 -1.10 ± 0.20 
NM_019499 MAD2 mitotic arrest deficient-like 1 (yeast) Mad2l1 1.87 ± 0.62 1.09 ± 0.34 -1.12 ± 0.25 
NM_023223 Cell division cycle 20 homolog (S. cerevisiae) Cdc20 1.87 ± 0.39 1.43 ± 0.31 -1.02 ± 0.24 
NM_026410 Cell division cycle associated 5 Cdca5 1.85 ± 0.44 1.26 ± 0.22 -1.11 ± 0.20 
NM_144818 Non-SMC condensin I complex, subunit H Ncaph 1.85 ± 0.64 1.28 ± 0.45 1.10 ± 0.34 
NM_028390 Anillin, actin binding protein Anln 1.84 ± 0.41 1.50 ± 0.33 1.18 ± 0.26 
NM_008682 
Neural precursor cell 
expressed, developmentally 
down-regulated gene 1 
Nedd1 1.71 ± 0.42 1.85 ± 0.40 1.36 ± 0.27 
NM_011497 Aurora kinase A AurkA 1.65 ± 0.40 1.31 ± 0.32 1.11 ± 0.26 
NM_016756 Cyclin-dependent kinase 2 Cdk2 1.60 ± 0.28 1.48 ± 0.26 1.33 ± 0.29 
NM_009773 
Budding uninhibited by 
benzimidazoles 1 homolog, 
beta (S. cerevisiae) 
Bub1b 1.60 ± 0.41 1.28 ± 0.39 -1.06 ± 0.26 
NM_053173 Kinesin family member C1 Kifc5a 1.59 ± 0.44 1.19 ± 0.26 1.01 ± 0.21 
NM_026560 Cell division cycle associated 8 Cdca8 1.58 ± 0.48 1.22 ± 0.32 1.01 ± 0.27 
NM_175384 Cell division cycle associated 2 Cdca2 1.57 ± 0.30 1.32 ± 0.25 -1.01 ± 0.20 
NM_013917 Pituitary tumor-transforming gene 1 Pttg1 1.57 ± 0.62 1.09 ± 0.29 -1.23 ± 0.21 
NM_026282 
SPC24, NDC80 kinetochore 
complex component, 
homolog (S. cerevisiae) 
Spc24 1.55 ± 0.50 1.29 ± 0.37 -1.06 ± 0.25 
NM_017407 Sperm associated antigen 5 Spag5 1.54 ± 0.37 1.43 ± 0.32 1.02 ± 0.22 
NM_010578 Integrin beta 1 (fibronectin receptor beta) Itgb1 1.54 ± 0.31 1.45 ± 0.29 1.10 ± 0.20 
NM_013726 DBF4 homolog (S. cerevisiae) Dbf4 1.51 ± 0.40 1.11 ± 0.23 1.28 ± 0.35 
NM_033270 E2F transcription factor 6 E2f6 1.41 ± 0.32 1.50 ± 0.24 1.15 ± 0.23 
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NM_031166 Inhibitor of DNA binding 4 Id4 1.36 ± 0.41 1.89 ± 0.53 1.15 ± 0.34 
NM_027985 MAD2 mitotic arrest deficient-like 2 (yeast) Mad2l2 1.33 ± 0.29 1.50 ± 0.37 1.05 ± 0.27 
NM_009831 Cyclin G1 Ccng1 1.30 ± 0.34 1.55 ± 0.33 1.25 ± 0.34 
NM_023317 Nuclear distribution gene E homolog 1 (A nidulans) Nde1 1.28 ± 0.32 1.56 ± 0.35 1.24 ± 0.30 
NM_019641 Stathmin 1 Stmn1 1.19 ± 0.39 -1.80 ± 0.16 -1.34 ± 0.22 
NM_023279 Tubulin, beta 3 class III Tubb3 1.02 ± 0.31 -1.77 ± 0.17 -1.66 ± 0.17 
NM_007631 Cyclin D1 Ccnd1 1.02 ± 0.31 -1.61 ± 0.15 -1.65 ± 0.15 
NM_008913 
Potein phosphatase 3, 
catalytic subunit, alpha 
isoform 
Ppp3ca -1.00 ± 0.23 -2.14 ± 0.09 -1.82 ± 0.21 
NM_134024 Tubulin, gamma 1 Tubg1 -1.04 ± 0.18 -1.34 ± 0.15 -1.76 ± 0.13 
NM_153058 
Microtubule-associated 
protein, RP/EB family, 
member 2 
Mapre2 -1.29 ± 0.16 -1.63 ± 0.11 -1.27 ± 0.25 
NM_183178 Fibronectin type 3 and SPRY domain-containing protein Fsd1 -1.30 ± 0.15 -1.72 ± 0.12 -1.69 ± 0.11 
NM_007595 
Calcium/calmodulin-
dependent protein kinase II, 
beta 
Camk2b -1.31 ± 0.13 -2.47 ± 0.06 -1.71 ± 0.11 
NM_133955 Ras homolog gene family, member U Rhou -1.53 ± 0.14 -1.50 ± 0.12 -1.22 ± 0.20 
NM_177407 
Calcium/calmodulin-
dependent protein kinase II 
alpha 
Camk2a -1.62 ± 0.18 -1.68 ± 0.16 -1.43 ± 0.17 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
Supplementary table 4. Significantly expressed genes (with fold-change of at least 1.5 in a minimum one 
out of three time-points and passed One-way ANOVA, p<0.05) encoding for proteins involved in mitotic cell 
cycle upon 250μM Glu-mediated excitotoxicity in cultured primary cortical neurons. Data are expressed as 
mean  sem.  
 
 250μM Glu 
Genbank Gene Symbol 5h 15h 24h 
Mitotic cell cycle 
NM_011121 Polo-like kinase 1 (Drosophila) Plk1 2.08 ± 0.32 2.06 ± 0.37 1.62 ± 0.30 
NM_007659 Cyclin-dependent kinase 1 Cdk1 2.06 ± 0.42 1.91 ± 0.47 1.50 ± 0.39 
NM_011497 Aurora kinase A AurkA 1.91 ± 0.42 1.98 ± 0.50 1.59 ± 0.44 
NM_026410 Cell division cycle associated 5 Cdca5 1.88 ± 0.45 1.60 ± 0.35 1.35 ± 0.33 
NM_175384 Cell division cycle associated 2 Cdca2 1.82 ± 0.37 1.70 ± 0.35 1.52 ± 0.34 
NM_028390 Anillin, actin binding protein Anln 1.80 ± 0.40 1.86 ± 0.51 1.67 ± 0.41 
NM_026282 
SPC24, NDC80 kinetochore 
complex component, homolog (S. 
cerevisiae) 
Spc24 1.71 ± 0.32 1.67 ± 0.55 1.18 ± 0.33 
NM_172301 Cyclin B1 Ccnb1 1.68 ± 0.42 2.09 ± 0.54 1.48 ± 0.51 
NM_025565 
SPC25, NDC80 kinetochore 
complex component, homolog (S. 
cerevisiae) 
Spc25 1.66 ± 0.41 1.85 ± 0.65 1.47 ± 0.63 
NM_023223 Cell division cycle 20 homolog (S. cerevisiae) Cdc20 1.61 ± 0.41 2.03 ± 0.50 1.32 ± 0.36 
NM_026560 Cell division cycle associated 8 Cdca8 1.61 ± 0.57 1.43 ± 0.48 1.06 ± 0.36 
NM_013538 Cell division cycle associated 3 Cdca3 1.57 ± 0.39 2.03 ± 0.48 1.43 ± 0.39 
NM_009689 Baculoviral IAP repeat-containing 5 Birc5 1.54 ± 0.36 1.88 ± 0.50 1.34 ± 0.30 
NM_017407 Sperm associated antigen 5 Spag5 1.52 ± 0.38 1.85 ± 0.46 1.55 ± 0.48 
NM_007893 E4F transcription factor 1 E4f1 1.52 ± 0.40 1.09 ± 0.33 1.03 ± 0.35 
NM_008682 
Neural precursor cell expressed, 
developmentally down-regulated 
gene 1 
Nedd1 1.40 ± 0.29 1.84 ± 0.42 1.65 ± 0.42 
NM_009831 Cyclin G1 Ccng 1.36 ± 0.31 1.52 ± 0.39 1.31 ± 0.29 
NM_010578 Integrin beta 1 (fibronectin receptor beta) Itgb1 1.34 ± 0.22 1.64 ± 0.28 1.46 ± 0.32 
NM_013917 Pituitary tumor-transforming gene 1 Pttg1 1.29 ± 0.44 1.71 ± 0.72 1.27 ± 0.45 
NM_144818 Non-SMC condensin I complex, subunit H Ncaph 1.24 ± 0.49 1.71 ± 0.55 1.53 ± 0.49 
NM_033270 E2F transcription factor 6 E2f6 1.22 ± 0.24 1.68 ± 0.42 1.53 ± 0.39 
NM_023317 Nuclear distribution gene E homolog 1 (A nidulans) Nde1 1.13 ± 0.30 1.77 ± 0.43 1.35 ± 0.35 
NM_022889 Pescadillo homolog 1, containing BRCT domain (zebrafish) Pes1 1.12 ± 0.22 1.49 ± 0.33 1.31 ± 0.28 
NM_007471 Amyloid beta (A4) precursor protein App 1.06 ± 0.20 -1.64 ± 0.12 -1.56 ± 0.14 
NM_008913 Protein phosphatase 3, catalytic subunit, alpha isoform Ppp3ca 1.03 ± 0.20 -1.71 ± 0.11 -1.48 ± 0.12 
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NM_007595 Calcium/calmodulin-dependent protein kinase II, beta Camk2b -1.18 ± 0.13 -2.33 ± 0.09 -1.74 ± 0.11 
NM_198429 
Nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent 1 
Nfatc1 -1.29 ± 0.23 1.50 ± 0.41 1.61 ± 0.45 
NM_153058 Microtubule-associated protein, RP/EB family, member 2 Mapre2 -1.29 ± 0.15 -1.51 ± 0.14 -1.27 ± 0.17 
NM_133955 Ras homolog gene family, member U Rhou -1.30 ± 0.16 -1.62 ± 0.15 -1.31 ± 0.14 
NM_152804 Polo-like kinase 2 (Drosophila) Plk2 -1.37 ± 0.18 -1.82 ± 0.12 -1.46 ± 0.20 
NM_031166 Inhibitor of DNA binding 4 Id4 -1.41 ± 0.21 1.93 ± 0.56 2.11 ± 0.76 
NM_177407 Calcium/calmodulin-dependent protein kinase II alpha Camk2a -1.42 ± 0.19 -1.67 ± 0.21 -1.44 ± 0.24 
 
